Cost Analysis of Implementing a 12-Month Recertification Criterion for Ryan White HIV/AIDS Program's AIDS Drug Assistance Program in Washington State

Public Health Rep. 2024 Sep-Oct;139(5):573-581. doi: 10.1177/00333549241227118. Epub 2024 Feb 8.

Abstract

Objective: AIDS Drug Assistance Programs (ADAPs) are state-administered programs that pay for medical care and medication for people living with HIV (PLWH) in the United States. In October 2021, the federal policy requiring that clients recertify for the program every 6 months was repealed, giving states the authority to set their own recertification policies. However, little data exist on the costs and health effects of alternative recertification schedules. We assessed the cost of changing the legacy 6-month recertification to a 12-month schedule in Washington State to inform policy decisions on recertification.

Methods: We used a Markov model to simulate the population of PLWH in Washington State who are eligible or enrolled in ADAP. We obtained model inputs and validation data from the Washington State Ryan White database. We estimated the cost of 12-month and 6-month criteria over a 5-year time horizon. Model outputs included annual program costs, population sizes, and number of people virally suppressed, by scenario.

Results: Under a continuation of the legacy 6-month recertification criteria, the annual cost of Washington ADAP would be $37 663 000 (95% CI, $34 570 000-$41 686 000) during the next 5 years, with a per-client cost of $7966 (95% CI, $7478-$8494). Under 12-month criteria, the annual cost would be $40 217 000 (95% CI, $36 243 000-$44 401 000) and the per-client cost would be $7543 (95% CI, $7084-$8042). Under the 12-month scenario, 245 more people will have been virally suppressed by the end of 2025.

Conclusions: Switching to a less frequent recertification process may improve health outcomes at a modest increase in cost in Washington State.

Keywords: HIV; Ryan White; health economics; structural barriers to care; viral suppression.

MeSH terms

  • Acquired Immunodeficiency Syndrome / drug therapy
  • Acquired Immunodeficiency Syndrome / economics
  • Anti-HIV Agents / economics
  • Anti-HIV Agents / therapeutic use
  • Costs and Cost Analysis
  • HIV Infections* / drug therapy
  • HIV Infections* / economics
  • Humans
  • Markov Chains
  • Medical Assistance / organization & administration
  • Washington

Substances

  • Anti-HIV Agents